Viread Pediatric Trials May Proceed Despite Bone Toxicity Potential - FDA

Gilead's Viread pediatric studies should proceed despite a potential risk of bone toxicity, FDA told the Antiviral Drugs Advisory Committee during its Oct. 3 review of the HIV treatment.